Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
RBC Capital analyst Luca Issi maintains $Beam Therapeutics(BEAM.US)$ with a hold rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 22.6% and
RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)
Jones Trading Initiates Coverage On Beam Therapeutics With Hold Rating
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
JonesTrading analyst Soumit Roy initiates coverage on $Beam Therapeutics(BEAM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 23.5% and a total average return
Hold Rating on Beam Therapeutics Amid Competitive Pressure and Absence of Clinical Data